Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy of recombinant humanized monoclonal anti-VEGF [vascular endothelial growth factor] antibody rhuMaB VEGF [bevacizumab] and EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] for locally advanced or metastatic non-squamous cell NSCLC [non-small cell lung cancer] in patients who have been previously treated.

Next Previous
X
Search
Trial Profile

Safety and efficacy of recombinant humanized monoclonal anti-VEGF [vascular endothelial growth factor] antibody rhuMaB VEGF [bevacizumab] and EGFR [epidermal growth factor receptor] tyrosine kinase inhibitor OSI-774 [erlotinib] for locally advanced or metastatic non-squamous cell NSCLC [non-small cell lung cancer] in patients who have been previously treated.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 27 Oct 2009 Additional lead trial nvestigator, actual patient number (41) identified as reported by ClinicalTrials.gov.
    • 27 Oct 2009 Primary endpoint added as reported by ClinicalTrials.gov.
    • 08 Jan 2008 Status changed from suspended to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top